Blood Tests Show Promise in Early Detection of Alzheimer’s Disease

Recent advancements in blood testing for Alzheimer’s disease have generated optimism among researchers and healthcare professionals. New studies indicate that tracking changes in specific protein biomarkers over time may yield more accurate results than relying on a single test. This emerging approach could serve as an effective early warning system for Alzheimer’s, potentially identifying the disease before traditional symptoms manifest.

Research presented at the annual meeting of the Radiological Society of North America revealed that obesity can obscure crucial signals of Alzheimer’s by diluting protein levels associated with the disease. A study highlighted that individuals who expressed concerns about their memory yet performed normally on cognitive tests exhibited a notable increase in these biomarkers over five years. This change was particularly pronounced among those with evidence of early Alzheimer’s in their spinal fluid, suggesting that initial cognitive tests may not capture the full picture.

Cyrus A. Raji, a neuroradiologist and principal investigator at the Neuroimaging Labs Research Center at Washington University School of Medicine, emphasized the significance of these findings, stating, “Twenty years ago, when I started medical school, we could only diagnose Alzheimer’s at autopsy. This has revolutionized the field.”

Advancements in Detection Technology

Traditionally, diagnosing Alzheimer’s involved brain scans or spinal taps, procedures that can be expensive and are often only performed during later stages of cognitive decline. Positron emission tomography (PET) scans, for example, utilize a radioactive tracer to highlight amyloid protein clumps in brain images. These clumps are thought to contribute to cognitive decline. Spinal taps measure the associated proteins in the fluid surrounding the brain and spinal cord.

Despite the established methods, Alzheimer’s diagnoses are on the rise, with many individuals remaining undiagnosed. In response, blood biomarker testing has rapidly gained traction in recent years. The U.S. Food and Drug Administration (FDA) has recently approved two blood tests designed to detect Alzheimer’s-related biomarkers. The Alzheimer’s Association has also issued clinical guidelines for their use in specialty care settings.

According to Sheena Aurora, a practicing neurologist and vice president of medical affairs at the Alzheimer’s Association, the FDA-approved tests serve different purposes. One functions as a “rule-out” test for primary care providers to assess whether amyloid buildup is influencing cognitive symptoms. The other is a “rule-in” test for specialists, indicating a higher likelihood of Alzheimer’s-linked proteins in the brain.

Aurora noted, “These tests are a tool,” and emphasized that they should be used alongside other diagnostic measures, such as family history and cognitive screening tests, rather than as stand-alone solutions. The tests are not intended for at-home use and must be ordered by a clinician experienced in dementia care.

Challenges and Limitations of Blood Tests

Despite the promise of blood-based tests, caution is warranted. Researchers have identified that chronic conditions can complicate the reliability of results. For instance, individuals with kidney issues may see skewed results, affecting the reliability of biomarkers related to Alzheimer’s. Findings from a study co-authored by Corey Bolton, a clinical neuropsychologist at Vanderbilt University Medical Center, revealed that mild kidney dysfunction significantly influences several key blood biomarkers, such as neurofilament light chain, which indicates nerve damage in the brain.

The Centers for Disease Control and Prevention estimates that approximately 34% of Americans over 65 suffer from chronic kidney disease, a condition that disproportionately affects certain communities. This prevalence heightens the need for a deeper understanding of how chronic conditions can affect Alzheimer’s blood tests.

Researchers are exploring solutions, such as comparing protein ratios, but acknowledge that most validation studies are conducted on relatively homogenous populations, which limits the applicability of findings across diverse groups. Argonde C. van Harten, a neurologist at the Alzheimer Center Amsterdam, emphasized the importance of personalized treatment as research progresses.

The necessity of longitudinal testing is another vital takeaway from the studies. Rather than depending on a single blood test, tracking protein levels over time provides a more comprehensive view of cognitive health. In a study that followed 298 participants who reported memory concerns but performed normally on cognitive assessments, researchers observed that those with increasing protein levels in their blood, particularly tau and glial fibrillary acidic proteins, experienced measurable declines in cognitive function over five years.

The study concluded that approximately 20% of participants who began with normal biomarker levels developed abnormal indicators over time. Harten highlighted that while their findings represent group-level trends, they are not individually predictive.

As testing technology evolves, experts believe that the early detection of Alzheimer’s disease can improve outcomes for patients. Raji stated, “If we can identify individuals who have Alzheimer’s disease before they have dementia, we can apply earlier treatments that may prevent the progression to dementia.”

While the path forward for blood-based biomarkers appears promising, clinicians and researchers stress the importance of using these tests judiciously and within appropriate contexts. The ongoing research and validation of these tests will play a crucial role in shaping future diagnostic approaches for Alzheimer’s disease.